drugset / Trial / NCT05688605
A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in combination with HX008 in patients with EGFR-positive advanced or metastatic solid tumors.
Timeline
- Start
- 2022-06-30
- Primary completion
- 2025-05
- Completion
- 2025-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Becotatug Vedotin | Monoclonal antibody | 1.5 mg/kg | Intravenous |
| Subject | Becotatug Vedotin | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Becotatug Vedotin | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | Pucotenlimab | Monoclonal antibody | 3 mg/kg | Intravenous |